Citations
Complex genotype in a GIST patient.
Genotipo complejo en un paciente con GIST.
Open | Download
How to Cite
1.
Becerra H, Cardona AF, Acevedo A, Vargas C, Carranza H, Otero J, et al. Complex genotype in a GIST patient. Rev. colomb. hematol. oncol. [Internet]. 2012 Apr. 1 [cited 2025 Dec. 5];1(1):70-7. https://doi.org/10.51643/22562915.291
Download Citation
Section
Reporte de caso
How to Cite
1.
Becerra H, Cardona AF, Acevedo A, Vargas C, Carranza H, Otero J, et al. Complex genotype in a GIST patient. Rev. colomb. hematol. oncol. [Internet]. 2012 Apr. 1 [cited 2025 Dec. 5];1(1):70-7. https://doi.org/10.51643/22562915.291
Dimensions
license
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Show authors biography
The case of a 35-year-old man is presented; he was diagnosed as having a gastrointestinal stromal tumour (GIST) which was located in the proximal jejunum and stratified as being high risk. The primary GIST was resected without evidence of relapse until multiple hepatic lesions were documented so that treatment with 400 mg/day imatinib (Glivec®) was begun. After progression was found, the inhibitor dose was increased without response, meaning that 50 mg/day sunitinib (Sutent®) was begun with the same result. The histotype and genotyping were thus re-evaluated, positivity for KIT gene exon 9 mutation being found; 400 mg BID sorafenib (Nexavar®) was administered from November 2009 onwards, achieving a 50% metabolic response (evaluated by PET/CAT) and partial response following the criteria described by Choi and coworkers. A new biopsy of the tumour was made during third-line treatment, demonstrating a complex genotype including the BRAF V600E mutation. Clinical benefit was maintained with the aforementioned intervention until July 2011; the patient was still alive at this point. A detailed analysis of the molecular mechanisms explaining resistance to tyrosine kinase inhibitors and the implications concerning GIST therapy was then proposed.
Article visits 201 | PDF visits 177
Downloads
Download data is not yet available.
- Rossi CR, Mocellin S, Mancarelli R, Foletto M, Pilati P, Nitti D, et al. Gastrointestinal stromal tumours: from a surgical to a molecular approach. Int J Cancer. 2003;107(2):171-6. DOI: https://doi.org/10.1002/ijc.11374
- Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003;65(3):187-97. DOI: https://doi.org/10.1159/000074470
- Thuneberg L. Interstitial cells of Cajal: intestinal pacemaker cells? Adv Anat Embryo Cell Biol. 1982;71:1-130. DOI: https://doi.org/10.1007/978-3-642-68417-3_1
- Chan JK. Mesenchymal tumours of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT). Implications of c-kit in genesis, and yet another of many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal disease? Adv Anat Pathol. 1999;6(1):19-40. DOI: https://doi.org/10.1097/00125480-199901000-00003
- Vargas C, Cardona AF, Carranza H, Otero JM, Reveiz L, Ospina E, et al. Tumores del estroma gastrointestinal (GIST): experiencia en dos instituciones hospitalarias de Bogotá D.C., Colombia (estudio del ONCOLGroup). Rev Col Gastroenterol. 2008;23(3):213-23.
- Oliveros R, Quintero AP, Sánchez R, Mesa JA. Tumores estromales gastrointestinales (GIST) en el Instituto Nacional de Cancerología (INC) 2000-2008. Rev Col Cancerol. 2011;15(4):1-34. DOI: https://doi.org/10.1016/S0123-9015(12)70050-1
- Nickl NJ. Gastrointestinal stromal tumors: new progress, new questions. Curr Opin Gastroenterol. 2004;20(5):482-7. DOI: https://doi.org/10.1097/00001574-200409000-00011
- Joensuu H, Roberts P, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052-6. DOI: https://doi.org/10.1056/NEJM200104053441404
- Joensuu H. Second line therapies for the treatment of gastrointestinal stromal tumor. Curr Opin Oncol. 2007;19(4):353- 8. DOI: https://doi.org/10.1097/CCO.0b013e3281338885
- Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418(6901):934. DOI: https://doi.org/10.1038/418934a
- Miranda C, Nucifora M, Molinari M, Conca E, Anania MC, Bordoni A, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(6):1769-76. DOI: https://doi.org/10.1158/1078-0432.CCR-11-2230
- Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83. DOI: https://doi.org/10.1053/j.semdp.2006.09.001
- Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch. 2010;456(2):111-27. DOI: https://doi.org/10.1007/s00428-010-0891-y
- Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459-65. DOI: https://doi.org/10.1053/hupa.2002.123545
- Fernández JA, Sánchez Canovas M, Parrilla P. Controversias en el tratamiento de los tumores del estroma gastrointestinal (GIST) primarios. Cir Esp. 2010;88:69-80. DOI: https://doi.org/10.1016/j.ciresp.2010.01.007
- Scarpa M, Bertin M, Ruffolo C, Polese L, D’Amico DF, Angriman I. A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol. 2008;98(5):384-92. DOI: https://doi.org/10.1002/jso.21120
- van de Rijn M, Hendrickson MR, Rouse RV. CD34 expression by gastrointestinal tract stromal tumors. Human Pathol. 1994:25(8):766-71. DOI: https://doi.org/10.1016/0046-8177(94)90245-3
- Downs-Kelly E, Rubi BP. Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies. Patholog Res Int. 2011;4:1-7. DOI: https://doi.org/10.4061/2011/708596
- Daniels M, Lurkin I, Pauli R, Erbstösser E, Hildebrandt U, Hellwig K, et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 2011;312(1):43-54. DOI: https://doi.org/10.1016/j.canlet.2011.07.029
- Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 2001;25(7):571-6. DOI: https://doi.org/10.1016/S0145-2126(01)00028-5
- Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors. Am J Surg Pathol. 2004;28(7):889-94. DOI: https://doi.org/10.1097/00000478-200407000-00007
- Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47(10):853-9. DOI: https://doi.org/10.1002/gcc.20589
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54. DOI: https://doi.org/10.1038/nature00766
- Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62(23):6997-7000.
- Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-15. DOI: https://doi.org/10.1056/NEJMoa1014209
- Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF (E600) in benign and malignant human tumours. Oncogene. 2008;27(7):877-95. DOI: https://doi.org/10.1038/sj.onc.1210704
- Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-47. DOI: https://doi.org/10.1056/NEJMoa050092
- Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182-90. DOI: https://doi.org/10.1158/1078-0432.CCR-04-2245
- Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-62. DOI: https://doi.org/10.1038/nature04304
- Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA. 2006;103(34):12843-8. DOI: https://doi.org/10.1073/pnas.0511076103
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16. DOI: https://doi.org/10.1056/NEJMoa1103782
- Nimeiri HS, Maki RG, Kasza K, D’Adamo D, Chow W, et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol. 2008;26:abstr 10502. DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.10502
- Kindler HL, Campbell NP, Wroblewski K, Maki RG, D’Adamo DR, Chow WA, et al. Sorafenib in patients with imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. J Clin Oncol. 2011;29:abstr 10009. DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.10009
- Cauchi C, Somaiah N, Engstrom P, Litwin S, López M, Lee L, et al. Evaluation of nilotinib (N) in advanced GIST previously treated with imatinibmesylate (IM) and sunitinib (S). J Clin Oncol. 2010;28:15s, abstr 10090. DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.10090
- Guo T, Agaram NP, Wong GC, Hom G, D’Adamo D, Maki RG, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007;13(16):4874-81. DOI: https://doi.org/10.1158/1078-0432.CCR-07-0484
- Italiano A, Cioffi A, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, et al. Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. J Clin Oncol. 2011;29:abstr 10044. DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.10044
- Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008;14(10):3204-15. DOI: https://doi.org/10.1158/1078-0432.CCR-07-1984
- Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol. 2011;8(3):161-70. DOI: https://doi.org/10.1038/nrclinonc.2011.3
Tutorials
About the journal
Information
Directories and Indexers
Plagiarism Check
Descriptor
Google Scholar profile
QR code
Keywords
Most read in the last 30 days
